JAK2 and essential thrombocythemia: The discovery of the JAK2 V617F mutation in 2005 and the revised 2008 World Health Organization (WHO) guidelines4 indicating a lower platelet count threshold for diagnosing ET, led to an apparent increase in ET incidence5.